Browse

Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer

DC Field Value Language
dc.contributor.authorSim, Eun Ji-
dc.contributor.authorKo, Kwang-Pil-
dc.contributor.authorAhn, Choonghyun-
dc.contributor.authorPark, Sang Min-
dc.contributor.authorSurh, Young-Joon-
dc.contributor.authorAn, Seokyung-
dc.contributor.authorKim, Sung-Won-
dc.contributor.authorLee, Min-Hyuk-
dc.contributor.authorLee, Jong Won-
dc.contributor.authorLee, Jeong Eon-
dc.contributor.authorKim, Ku Sang-
dc.contributor.authorYom, Cha Kyong-
dc.contributor.authorKim, Hyun-Ah-
dc.contributor.authorPark, Sue K.-
dc.date.accessioned2021-01-31T09:18:35Z-
dc.date.available2021-01-31T09:18:35Z-
dc.date.issued2020-11-
dc.identifier.citationBreast Cancer Research and Treatment, Vol.184 No.2, pp.615-626-
dc.identifier.issn0167-6806-
dc.identifier.other115470-
dc.identifier.urihttps://hdl.handle.net/10371/172558-
dc.description.abstractPurpose We investigated the association between isoflavone (ISF) intake and hereditary breast cancer (BC) risk, particularly by molecular subtype, in East-AsianBRCA1/2mutation carriers and non-carriers at a high risk of hereditary breast cancer (i.e., family history of BC (FHBC) and early-onset BC [EOBC, age < 40 years]). Methods The association between ISF intake and BC risk by molecular subtypes was assessed in 1709 participants (407BRCA1/2carriers, 585 FHBC non-carriers, 586 EOBC non-carriers, and 131 unaffected non-carriers) from the Korean Hereditary Breast Cancer Study using hazard ratios (HRs) and 95% confidence intervals (CIs) in weighted Cox regression models. Daily ISF intake was assessed using a validated food frequency questionnaire. We evaluated gene-environment interactions betweenBRCA1/2mutation and ISF intake in 1604 BC cases by calculating the case-only odds ratios (CORs) and 95% CIs in logistic regression models. Results ISF intake was inversely associated with luminal A BC risk inBRCA2mutation carriers and FHBC non-carriers (HR = 0.14, 95% CI = 0.04-0.50 for high intake [ISF intake >= 15.50 mg/day]; HR = 0.27, 95% CI = 0.11-0.69 for high intake, respectively). We observed a reduced risk of triple negative BC (TNBC) inBRCA1carriers and FHBC non-carriers (HR = 0.09, 95% CI = 0.02-0.40 for high intake; HR = 0.19, 95% CI = 0.05-0.69 for high intake, respectively). In the case-only design, an interaction betweenBRCA1mutation carrier status and ISF intake emerged in TNBC patients (COR = 0.39, 95% CI = 0.16-0.95). Conclusions This study suggests that ISF intake is inversely associated with BC risk in women at high risk of hereditary BC and that the effect could differ by molecular subtypes.-
dc.subjectHereditary breast cancer syndrome-
dc.subjectFamilial breast cancer-
dc.subjectBRCAmutation-
dc.subjectIsoflavones-
dc.subjectSoy-
dc.subjectMolecular subtypes-
dc.titleIsoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor서영준-
dc.identifier.doi10.1007/s10549-020-05875-0-
dc.citation.journaltitleBreast Cancer Research and Treatment-
dc.identifier.scopusid2-s2.0-85092661371-
dc.citation.endpage626-
dc.citation.number2-
dc.citation.startpage615-
dc.citation.volume184-
dc.identifier.urlhttps://link.springer.com/article/10.1007/s10549-020-05875-0-
dc.identifier.rimsid115470-
dc.identifier.sci000579666500003-
dc.contributor.affiliatedAuthorSurh, Young-Joon-
Appears in Collections:
Graduate School of Convergence Science and Technology (융합과학기술대학원)Dept. of Molecular and Biopharmaceutical Sciences (분자의학 및 바이오제약학과)Journal Papers (저널논문_분자의학 및 바이오제약학과)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse